A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Rilzabrutinib (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Acronyms RILECSU
- Sponsors Sanofi
- 22 May 2024 This trial has been completed in Greece (End date:2024-04-23 ) according to European Clinical Trials Database record.
- 26 Apr 2024 Status changed from active, no longer recruiting to completed.
- 24 Feb 2024 According to a Sanofi media release, results from this phase 2 study of rilzabrutinib forms the basis for Phase 3 CSU and prurigo nodularis program to start in 2024.